Claris Ventures, €85 Million Closing for the Turin-based Sgr Focused on Early-Stage Biotech
Claris Ventures, founded by Pietro Puglisi and Ciro Spedaliere, is thus confirmed as one of the main Italian operators with a focus on early-stage biotech, a sector of strategic importance for the country. Two investments are already in the portfolio, one in the immuno-oncology field and the other in the metabolic field, for a total of $28 million (€24 million).
Claris Ventures Sgr has announced the closing of subscriptions for the “Claris Biotech I” fund and the “Claris Biotech I – Parallel fund”, for a total of $100 million (€85 million). As stated in a note, the capital raised will be invested primarily in new Italian biotech companies engaged in the development of drugs for the treatment of diseases with high clinical needs.
The final closing sees the entry of the European Investment Fund (EIF), with a subscription of $47 million (€40 million), and a further subscription of $11.7 million (€10 million) by CDP Venture Capital on behalf of the Mise Co-investment Fund, which follows previous subscriptions by CDP Venture Capital on behalf of FOF VenturItaly, Fondazione Compagnia di San Paolo, Inarcassa, Ersel, and other private individuals and family offices.
If you want to find more details about Claris Ventures and its closing of subscriptions for “Claris Biotech I” fund and the “Claris Biotech I – Parallel fund”, for a total of $100 million (€85 million), download for free our companion app. The Born2Invest mobile app keeps its readers up to date with the latest finance news in the world and the most important market updates.
Comments on the operation
“The importance of early-stage initiatives in biotech can easily be underestimated. It is our job to ensure that the necessary capital is available so that technologies that can change our lives can reach their full potential,” commented Alessandro Tappi, director of Fei.
“We enthusiastically renew our trust in Claris Ventures, which supports the birth and growth of Italian biotech companies, now more than ever at the center of national and international interest,” said Enrico Resmini, managing director and general manager of Cdp Venture Capital Sgr.
The commitment of Claris Ventures
Claris Ventures, founded by Pietro Puglisi and Ciro Spedaliere, is thus confirmed as one of the main Italian operators with a focus on early-stage biotech, a sector of strategic importance for the country. “The trust placed in Claris Ventures by important national and international institutions allows us to contribute decisively to the development of the Italian biotech sector, creating a positive impact on patients and generating economic and social value at the same time,” commented Puglisi and Spedaliere.
Two investments are already in the portfolio, one in the immuno-oncology field and the other in the metabolic field. The investment rounds in the first two companies, for a total of $28 million (€24 million), were led by Claris Ventures as lead investor and saw the participation of international investors and pharmaceutical companies.
(Featured image by Visual Stories via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in StartupItalia, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Consolidation of the Fintech Sector Reinforces Mastercard’s Commitment to the Sector
Mauricio Schwartzmann, CEO of Mastercard Mexico, stressed that the firm's involvement with financial technology is long-term and goes hand in...
Canal de Isabel II Accelerates Towards Energy Self-Consumption
Canal de Isabel II will switch from the then state-of-the-art Pelton turbines of 1913 to producing green hydrogen from reclaimed...
Dogecoin: Doge Whales Return Due to Bullish Metrics
In the short term, Dogecoin is encountering its first major resistance at $0.075, although a larger obstacle lies at $0.08....
Exit for Kippy, which Had Closed Two Equity Crowdfunding Rounds
Kippy recently participated in the third batch of the A-Road acceleration and fundraising program which, through ongoing training and mentorship...
Laminar Pharma Opens a €5 Million Round through Capital Cell
Looking ahead to 2024, the group plans to reach break-even, when the European Medicines Agency approves its drug against glioblastoma,...
Crypto2 weeks ago
Ripple: Could Wiping Out XRP Reserves End SEC Lawsuit?
Crypto3 days ago
Bitcoin: Ordinals Attract Former Ethereum Developers
Featured1 week ago
Coffee Producers in Vietnam and Indonesia Are Said to Have Almost Nothing Left to Sell
Cannabis7 days ago
Where Do Cannabis Users Buy Cannabis From: New Frontier Data Study